| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Living Donors | 84 | 2024 | 339 | 14.190 |
Why?
|
| Uterus | 51 | 2024 | 222 | 14.130 |
Why?
|
| Tissue and Organ Procurement | 37 | 2024 | 345 | 11.500 |
Why?
|
| Liver Transplantation | 74 | 2024 | 1177 | 10.720 |
Why?
|
| Infertility, Female | 26 | 2024 | 96 | 8.700 |
Why?
|
| Organ Transplantation | 30 | 2024 | 275 | 7.020 |
Why?
|
| Kidney Transplantation | 29 | 2024 | 849 | 5.540 |
Why?
|
| Tissue Donors | 32 | 2024 | 490 | 4.920 |
Why?
|
| Hepatectomy | 13 | 2023 | 170 | 3.740 |
Why?
|
| Liver | 20 | 2023 | 1205 | 3.420 |
Why?
|
| Transplant Recipients | 11 | 2024 | 137 | 3.380 |
Why?
|
| Organ Preservation | 9 | 2024 | 105 | 2.870 |
Why?
|
| Informed Consent | 8 | 2024 | 275 | 2.580 |
Why?
|
| Live Birth | 7 | 2024 | 17 | 2.470 |
Why?
|
| Robotic Surgical Procedures | 5 | 2023 | 304 | 2.280 |
Why?
|
| Perfusion | 9 | 2024 | 235 | 2.190 |
Why?
|
| End Stage Liver Disease | 7 | 2023 | 60 | 2.190 |
Why?
|
| Graft Survival | 31 | 2024 | 898 | 2.150 |
Why?
|
| Humans | 201 | 2024 | 89073 | 2.130 |
Why?
|
| Transplants | 4 | 2021 | 41 | 1.750 |
Why?
|
| Female | 124 | 2024 | 46014 | 1.630 |
Why?
|
| Pregnancy | 28 | 2024 | 3010 | 1.620 |
Why?
|
| Donor Selection | 6 | 2022 | 74 | 1.610 |
Why?
|
| 46, XX Disorders of Sex Development | 6 | 2024 | 10 | 1.550 |
Why?
|
| Liver Regeneration | 3 | 2021 | 36 | 1.530 |
Why?
|
| Graft Rejection | 14 | 2024 | 1067 | 1.420 |
Why?
|
| Adult | 90 | 2024 | 26508 | 1.330 |
Why?
|
| Postoperative Complications | 27 | 2024 | 2275 | 1.290 |
Why?
|
| Death | 8 | 2024 | 85 | 1.270 |
Why?
|
| Hysterectomy | 8 | 2023 | 151 | 1.270 |
Why?
|
| Embryo Transfer | 4 | 2023 | 30 | 1.240 |
Why?
|
| Reperfusion Injury | 4 | 2022 | 140 | 1.110 |
Why?
|
| Hepatic Artery | 8 | 2017 | 84 | 1.100 |
Why?
|
| Hepatic Veins | 3 | 2022 | 26 | 1.070 |
Why?
|
| Laparoscopy | 4 | 2022 | 771 | 1.070 |
Why?
|
| Bile Ducts | 7 | 2018 | 59 | 1.020 |
Why?
|
| Anastomosis, Surgical | 15 | 2024 | 273 | 1.020 |
Why?
|
| Waiting Lists | 6 | 2021 | 183 | 0.990 |
Why?
|
| Patient Selection | 10 | 2021 | 682 | 0.940 |
Why?
|
| Pancreas Transplantation | 4 | 2021 | 104 | 0.910 |
Why?
|
| Treatment Outcome | 35 | 2024 | 8203 | 0.900 |
Why?
|
| Biliary Tract | 1 | 2022 | 12 | 0.850 |
Why?
|
| Brain Death | 1 | 2024 | 82 | 0.850 |
Why?
|
| Fatty Liver | 3 | 2022 | 95 | 0.820 |
Why?
|
| ABO Blood-Group System | 4 | 2014 | 58 | 0.810 |
Why?
|
| Fertility | 3 | 2024 | 116 | 0.800 |
Why?
|
| Fees and Charges | 1 | 2021 | 14 | 0.800 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 179 | 0.780 |
Why?
|
| Serum Sickness | 1 | 2021 | 12 | 0.780 |
Why?
|
| Alemtuzumab | 1 | 2021 | 85 | 0.770 |
Why?
|
| Middle Aged | 59 | 2024 | 25865 | 0.770 |
Why?
|
| Retrospective Studies | 30 | 2024 | 9003 | 0.750 |
Why?
|
| Ileum | 6 | 2009 | 160 | 0.740 |
Why?
|
| Vaccines | 1 | 2022 | 83 | 0.740 |
Why?
|
| Health Policy | 1 | 2021 | 184 | 0.690 |
Why?
|
| Resource Allocation | 1 | 2020 | 65 | 0.690 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.680 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 167 | 0.680 |
Why?
|
| Health Resources | 1 | 2020 | 81 | 0.670 |
Why?
|
| Tissue and Organ Harvesting | 7 | 2023 | 78 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 195 | 0.650 |
Why?
|
| Nephrectomy | 4 | 2015 | 293 | 0.640 |
Why?
|
| Immunosuppressive Agents | 13 | 2023 | 975 | 0.630 |
Why?
|
| United States | 14 | 2024 | 6957 | 0.610 |
Why?
|
| Decision Making | 3 | 2021 | 665 | 0.610 |
Why?
|
| Pancreatitis, Chronic | 3 | 2023 | 54 | 0.600 |
Why?
|
| Allografts | 3 | 2024 | 181 | 0.600 |
Why?
|
| Male | 76 | 2024 | 42254 | 0.600 |
Why?
|
| Intestine, Small | 9 | 2017 | 299 | 0.600 |
Why?
|
| Physicians | 3 | 2022 | 689 | 0.590 |
Why?
|
| Vena Cava, Inferior | 4 | 2015 | 145 | 0.590 |
Why?
|
| Motivation | 4 | 2023 | 296 | 0.590 |
Why?
|
| Biliary Tract Surgical Procedures | 3 | 2017 | 11 | 0.580 |
Why?
|
| Young Adult | 14 | 2024 | 6289 | 0.570 |
Why?
|
| Beneficence | 2 | 2014 | 34 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.570 |
Why?
|
| Congenital Abnormalities | 5 | 2024 | 64 | 0.550 |
Why?
|
| Time Factors | 16 | 2021 | 5320 | 0.550 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 362 | 0.540 |
Why?
|
| Hepatic Duct, Common | 2 | 2006 | 10 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2022 | 2657 | 0.520 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 424 | 0.520 |
Why?
|
| Vascular Neoplasms | 1 | 2015 | 21 | 0.520 |
Why?
|
| Fertilization in Vitro | 4 | 2024 | 57 | 0.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 531 | 0.510 |
Why?
|
| Ethical Analysis | 3 | 2023 | 23 | 0.510 |
Why?
|
| Ethics, Medical | 4 | 2012 | 307 | 0.510 |
Why?
|
| Leiomyosarcoma | 1 | 2015 | 45 | 0.500 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.490 |
Why?
|
| Personal Autonomy | 2 | 2014 | 116 | 0.490 |
Why?
|
| Mullerian Ducts | 4 | 2024 | 18 | 0.480 |
Why?
|
| Follow-Up Studies | 14 | 2024 | 3657 | 0.480 |
Why?
|
| Moral Obligations | 2 | 2012 | 53 | 0.470 |
Why?
|
| Liver Cirrhosis | 7 | 2020 | 254 | 0.470 |
Why?
|
| Portal Vein | 5 | 2017 | 120 | 0.470 |
Why?
|
| Unrelated Donors | 1 | 2014 | 45 | 0.470 |
Why?
|
| Liver Failure, Acute | 4 | 2011 | 39 | 0.470 |
Why?
|
| Bioethical Issues | 1 | 2014 | 38 | 0.470 |
Why?
|
| Risk Factors | 16 | 2024 | 5466 | 0.470 |
Why?
|
| Liver Diseases | 7 | 2023 | 242 | 0.460 |
Why?
|
| Intestines | 4 | 2011 | 416 | 0.440 |
Why?
|
| Tacrolimus | 9 | 2023 | 369 | 0.430 |
Why?
|
| Hypertension, Portal | 2 | 2011 | 46 | 0.430 |
Why?
|
| Patient Acuity | 2 | 2023 | 33 | 0.430 |
Why?
|
| Choledochostomy | 1 | 2012 | 8 | 0.420 |
Why?
|
| Child | 19 | 2022 | 7149 | 0.420 |
Why?
|
| Coercion | 1 | 2012 | 15 | 0.400 |
Why?
|
| Pregnancy Outcome | 3 | 2023 | 253 | 0.400 |
Why?
|
| Quality of Life | 5 | 2023 | 1662 | 0.400 |
Why?
|
| Texas | 3 | 2021 | 113 | 0.400 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 42 | 0.390 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2022 | 241 | 0.390 |
Why?
|
| Abdomen | 3 | 2024 | 122 | 0.380 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2011 | 12 | 0.380 |
Why?
|
| Blood Group Incompatibility | 2 | 2008 | 20 | 0.380 |
Why?
|
| Jejunostomy | 2 | 2014 | 14 | 0.380 |
Why?
|
| Aneurysm, False | 2 | 2008 | 54 | 0.370 |
Why?
|
| Liver Neoplasms | 5 | 2012 | 754 | 0.370 |
Why?
|
| Biliary Tract Diseases | 4 | 2024 | 36 | 0.370 |
Why?
|
| Qualitative Research | 2 | 2023 | 291 | 0.370 |
Why?
|
| Aorta, Abdominal | 2 | 2009 | 59 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2012 | 390 | 0.360 |
Why?
|
| Medical Tourism | 1 | 2010 | 5 | 0.360 |
Why?
|
| Program Development | 2 | 2010 | 123 | 0.350 |
Why?
|
| Commerce | 1 | 2010 | 31 | 0.350 |
Why?
|
| Ethics | 1 | 2009 | 24 | 0.340 |
Why?
|
| Histocompatibility | 1 | 2009 | 66 | 0.330 |
Why?
|
| Ischemic Preconditioning | 1 | 2009 | 37 | 0.330 |
Why?
|
| Prospective Studies | 8 | 2024 | 4273 | 0.330 |
Why?
|
| Thrombosis | 4 | 2023 | 302 | 0.330 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 66 | 0.320 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2008 | 35 | 0.310 |
Why?
|
| Transplantation, Homologous | 6 | 2022 | 996 | 0.310 |
Why?
|
| Elective Surgical Procedures | 1 | 2009 | 126 | 0.310 |
Why?
|
| General Surgery | 2 | 2017 | 235 | 0.300 |
Why?
|
| Infant, Newborn | 6 | 2024 | 2476 | 0.300 |
Why?
|
| Cohort Studies | 4 | 2023 | 2863 | 0.300 |
Why?
|
| Prognosis | 5 | 2024 | 3773 | 0.290 |
Why?
|
| Splenic Artery | 1 | 2006 | 11 | 0.280 |
Why?
|
| Transplantation, Autologous | 5 | 2023 | 343 | 0.280 |
Why?
|
| Peliosis Hepatis | 1 | 2006 | 1 | 0.280 |
Why?
|
| Liver Failure | 4 | 2012 | 67 | 0.280 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 625 | 0.270 |
Why?
|
| Anastomotic Leak | 3 | 2024 | 103 | 0.270 |
Why?
|
| Stomach | 1 | 2006 | 111 | 0.260 |
Why?
|
| Vascular Surgical Procedures | 1 | 2007 | 149 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2022 | 865 | 0.260 |
Why?
|
| Venous Thrombosis | 3 | 2017 | 250 | 0.260 |
Why?
|
| Infant | 12 | 2022 | 3147 | 0.260 |
Why?
|
| Single Embryo Transfer | 2 | 2024 | 2 | 0.250 |
Why?
|
| Organ Preservation Solutions | 2 | 2013 | 28 | 0.250 |
Why?
|
| Hospitals | 3 | 2023 | 299 | 0.250 |
Why?
|
| Pregnancy Rate | 2 | 2024 | 21 | 0.250 |
Why?
|
| Liver Circulation | 2 | 2004 | 29 | 0.250 |
Why?
|
| Ovulation Induction | 2 | 2024 | 34 | 0.250 |
Why?
|
| Pelvis | 2 | 2022 | 96 | 0.250 |
Why?
|
| Kidney | 4 | 2022 | 1145 | 0.240 |
Why?
|
| Preoperative Care | 3 | 2018 | 396 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1176 | 0.240 |
Why?
|
| Cause of Death | 2 | 2023 | 266 | 0.230 |
Why?
|
| Raffinose | 1 | 2003 | 23 | 0.230 |
Why?
|
| Procaine | 1 | 2003 | 11 | 0.230 |
Why?
|
| Potassium Chloride | 1 | 2003 | 86 | 0.220 |
Why?
|
| Mannitol | 1 | 2003 | 50 | 0.220 |
Why?
|
| Biopsy | 3 | 2022 | 1182 | 0.220 |
Why?
|
| Allopurinol | 1 | 2003 | 77 | 0.220 |
Why?
|
| Glutathione | 1 | 2003 | 108 | 0.220 |
Why?
|
| Uterine Artery | 1 | 2023 | 6 | 0.220 |
Why?
|
| Umbilical Arteries | 1 | 2023 | 17 | 0.220 |
Why?
|
| Cesarean Section | 2 | 2021 | 140 | 0.220 |
Why?
|
| Child, Preschool | 11 | 2022 | 3717 | 0.220 |
Why?
|
| Vagina | 1 | 2024 | 173 | 0.210 |
Why?
|
| Fetal Growth Retardation | 1 | 2023 | 67 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 705 | 0.210 |
Why?
|
| Regional Blood Flow | 3 | 2017 | 198 | 0.210 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1067 | 0.210 |
Why?
|
| Cholestasis | 3 | 2017 | 45 | 0.210 |
Why?
|
| Plasmapheresis | 4 | 2014 | 25 | 0.210 |
Why?
|
| Adolescent | 17 | 2021 | 9237 | 0.210 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 738 | 0.200 |
Why?
|
| Disease Progression | 2 | 2024 | 1488 | 0.200 |
Why?
|
| Intestinal Diseases | 2 | 2017 | 79 | 0.200 |
Why?
|
| Premature Birth | 1 | 2024 | 117 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2024 | 779 | 0.200 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 46 | 0.200 |
Why?
|
| Policy | 1 | 2022 | 35 | 0.200 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2003 | 120 | 0.200 |
Why?
|
| Survival Rate | 9 | 2024 | 1889 | 0.200 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 20 | 0.200 |
Why?
|
| Pancreatectomy | 4 | 2023 | 158 | 0.200 |
Why?
|
| Risk | 2 | 2014 | 657 | 0.190 |
Why?
|
| Specialization | 1 | 2001 | 65 | 0.190 |
Why?
|
| Reoperation | 6 | 2017 | 598 | 0.190 |
Why?
|
| Body Weight | 3 | 2014 | 452 | 0.190 |
Why?
|
| Hospitals, University | 1 | 2001 | 195 | 0.190 |
Why?
|
| Organ Size | 3 | 2018 | 369 | 0.190 |
Why?
|
| Heparin | 1 | 2022 | 185 | 0.190 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 153 | 0.190 |
Why?
|
| Sick Leave | 1 | 2021 | 13 | 0.190 |
Why?
|
| Parity | 1 | 2021 | 96 | 0.190 |
Why?
|
| Patient Safety | 2 | 2014 | 216 | 0.190 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 53 | 0.190 |
Why?
|
| Incidence | 6 | 2024 | 1592 | 0.190 |
Why?
|
| Terminal Care | 1 | 2022 | 137 | 0.180 |
Why?
|
| Morals | 1 | 2022 | 94 | 0.180 |
Why?
|
| Adenosine | 1 | 2003 | 237 | 0.180 |
Why?
|
| Glucose | 1 | 2003 | 630 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 146 | 0.180 |
Why?
|
| Operative Time | 1 | 2021 | 142 | 0.180 |
Why?
|
| Blood Loss, Surgical | 1 | 2021 | 115 | 0.180 |
Why?
|
| Renal Dialysis | 2 | 2021 | 335 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2024 | 398 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2021 | 334 | 0.170 |
Why?
|
| International Cooperation | 1 | 2019 | 125 | 0.170 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 254 | 0.170 |
Why?
|
| Recovery of Function | 1 | 2021 | 292 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2014 | 62 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 275 | 0.160 |
Why?
|
| Length of Stay | 2 | 2021 | 732 | 0.160 |
Why?
|
| Cholangiography | 2 | 2012 | 40 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 311 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2018 | 68 | 0.150 |
Why?
|
| Insulin | 1 | 2003 | 1146 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 643 | 0.150 |
Why?
|
| Age Factors | 4 | 2017 | 1867 | 0.150 |
Why?
|
| Iliac Vein | 3 | 2007 | 30 | 0.150 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 345 | 0.150 |
Why?
|
| Heart Transplantation | 1 | 2023 | 717 | 0.150 |
Why?
|
| Sexual Partners | 1 | 2018 | 100 | 0.150 |
Why?
|
| Asia | 1 | 2017 | 98 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1223 | 0.140 |
Why?
|
| North America | 1 | 2017 | 184 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 5 | 2009 | 413 | 0.140 |
Why?
|
| Europe | 1 | 2017 | 321 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 570 | 0.140 |
Why?
|
| Mass Screening | 1 | 2021 | 636 | 0.140 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 205 | 0.140 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 195 | 0.130 |
Why?
|
| Thrombectomy | 1 | 2017 | 172 | 0.130 |
Why?
|
| Liver Function Tests | 5 | 2007 | 92 | 0.130 |
Why?
|
| Short Bowel Syndrome | 2 | 2006 | 38 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 257 | 0.120 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2014 | 64 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2005 | 111 | 0.120 |
Why?
|
| Bile Duct Diseases | 1 | 2014 | 22 | 0.120 |
Why?
|
| Enbucrilate | 1 | 2014 | 7 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1149 | 0.120 |
Why?
|
| Steroids | 2 | 2005 | 174 | 0.120 |
Why?
|
| Biomarkers | 2 | 2019 | 1755 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 2 | 2008 | 205 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 1837 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 771 | 0.120 |
Why?
|
| Ablation Techniques | 1 | 2014 | 36 | 0.110 |
Why?
|
| Stents | 3 | 2018 | 395 | 0.110 |
Why?
|
| Blood Flow Velocity | 3 | 2023 | 198 | 0.110 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2014 | 52 | 0.110 |
Why?
|
| Social Justice | 1 | 2014 | 54 | 0.110 |
Why?
|
| Aged | 10 | 2020 | 19078 | 0.110 |
Why?
|
| Islam | 1 | 2013 | 36 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 390 | 0.110 |
Why?
|
| Health Education | 1 | 2013 | 105 | 0.110 |
Why?
|
| Clinical Protocols | 2 | 2004 | 157 | 0.110 |
Why?
|
| Swine | 2 | 2012 | 581 | 0.110 |
Why?
|
| Isoantibodies | 1 | 2014 | 119 | 0.110 |
Why?
|
| Spleen | 2 | 2022 | 432 | 0.110 |
Why?
|
| Complement C4b | 2 | 2014 | 32 | 0.110 |
Why?
|
| Cell Membrane Permeability | 1 | 2013 | 120 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2014 | 268 | 0.110 |
Why?
|
| Histology | 1 | 2012 | 4 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2014 | 227 | 0.100 |
Why?
|
| Biomedical Engineering | 1 | 2012 | 20 | 0.100 |
Why?
|
| Cyclosporine | 4 | 2005 | 237 | 0.100 |
Why?
|
| Fatal Outcome | 3 | 2008 | 299 | 0.100 |
Why?
|
| Jejunum | 1 | 2012 | 80 | 0.100 |
Why?
|
| Paternalism | 1 | 2012 | 24 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 461 | 0.100 |
Why?
|
| Abdominal Wall | 2 | 2009 | 30 | 0.100 |
Why?
|
| Parenteral Nutrition, Total | 3 | 2009 | 41 | 0.100 |
Why?
|
| Robotics | 2 | 2006 | 269 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2017 | 780 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 170 | 0.100 |
Why?
|
| Birth Weight | 2 | 2022 | 145 | 0.100 |
Why?
|
| Equipment Design | 1 | 2012 | 415 | 0.090 |
Why?
|
| Mesenteric Veins | 1 | 2011 | 33 | 0.090 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 2014 | 26 | 0.090 |
Why?
|
| Gastroschisis | 2 | 2008 | 13 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1975 | 0.090 |
Why?
|
| Constriction, Pathologic | 2 | 2024 | 217 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 358 | 0.090 |
Why?
|
| Body Height | 2 | 2008 | 100 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 142 | 0.090 |
Why?
|
| Abdominal Cavity | 2 | 2008 | 18 | 0.090 |
Why?
|
| Recurrence | 3 | 2009 | 1140 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2014 | 463 | 0.090 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2011 | 83 | 0.090 |
Why?
|
| Capital Punishment | 1 | 2010 | 3 | 0.090 |
Why?
|
| Ultrasonography, Doppler | 2 | 2023 | 85 | 0.090 |
Why?
|
| Animals | 4 | 2021 | 27324 | 0.090 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2009 | 19 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2012 | 684 | 0.090 |
Why?
|
| Internationality | 1 | 2010 | 69 | 0.090 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 12 | 0.090 |
Why?
|
| Social Responsibility | 1 | 2010 | 57 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2014 | 137 | 0.090 |
Why?
|
| Mycophenolic Acid | 3 | 2023 | 84 | 0.080 |
Why?
|
| Prisoners | 1 | 2010 | 45 | 0.080 |
Why?
|
| Aneurysm | 1 | 2009 | 60 | 0.080 |
Why?
|
| China | 1 | 2010 | 233 | 0.080 |
Why?
|
| Ileal Neoplasms | 1 | 2009 | 9 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 77 | 0.080 |
Why?
|
| Judgment | 1 | 2010 | 67 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2012 | 280 | 0.080 |
Why?
|
| Bacteria | 1 | 2013 | 472 | 0.080 |
Why?
|
| Rituximab | 1 | 2009 | 119 | 0.080 |
Why?
|
| Antilymphocyte Serum | 2 | 2005 | 70 | 0.080 |
Why?
|
| Omentum | 1 | 2009 | 73 | 0.080 |
Why?
|
| Rupture | 1 | 2008 | 61 | 0.080 |
Why?
|
| Angiography | 2 | 2006 | 208 | 0.080 |
Why?
|
| Stomach Volvulus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2008 | 75 | 0.080 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2008 | 51 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 805 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2017 | 1041 | 0.080 |
Why?
|
| Guanine | 1 | 2008 | 207 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2009 | 171 | 0.070 |
Why?
|
| Colectomy | 1 | 2009 | 172 | 0.070 |
Why?
|
| Psoas Muscles | 1 | 2007 | 2 | 0.070 |
Why?
|
| Minocycline | 1 | 2007 | 15 | 0.070 |
Why?
|
| Citrulline | 1 | 2007 | 10 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 1401 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2008 | 140 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 226 | 0.070 |
Why?
|
| Foreign-Body Migration | 1 | 2007 | 39 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2006 | 278 | 0.070 |
Why?
|
| Creatinine | 3 | 2020 | 293 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2007 | 62 | 0.070 |
Why?
|
| Syndrome | 2 | 2023 | 449 | 0.070 |
Why?
|
| Growth Disorders | 1 | 2006 | 63 | 0.070 |
Why?
|
| Vasculitis | 1 | 2006 | 40 | 0.070 |
Why?
|
| Transplantation | 1 | 2006 | 38 | 0.070 |
Why?
|
| Survivors | 1 | 2008 | 233 | 0.070 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2002 | 21 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 359 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 237 | 0.070 |
Why?
|
| Factor VII | 1 | 2005 | 2 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2020 | 222 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2006 | 53 | 0.060 |
Why?
|
| Device Removal | 1 | 2007 | 167 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2005 | 74 | 0.060 |
Why?
|
| Transplantation Tolerance | 1 | 2007 | 138 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2008 | 475 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 55 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 233 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1591 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 859 | 0.060 |
Why?
|
| Child Development | 1 | 2006 | 167 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2005 | 42 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 188 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 573 | 0.060 |
Why?
|
| Bioethics | 1 | 2005 | 35 | 0.060 |
Why?
|
| Biliary Atresia | 1 | 2004 | 22 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2008 | 1533 | 0.060 |
Why?
|
| Octreotide | 1 | 2004 | 23 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2004 | 46 | 0.060 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2004 | 69 | 0.060 |
Why?
|
| Forecasting | 2 | 2022 | 305 | 0.060 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2003 | 6 | 0.060 |
Why?
|
| Spain | 1 | 2023 | 32 | 0.060 |
Why?
|
| Pneumoperitoneum | 1 | 2003 | 4 | 0.060 |
Why?
|
| Cervix Uteri | 1 | 2024 | 70 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 71 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 2003 | 36 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2005 | 306 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2004 | 110 | 0.060 |
Why?
|
| Public Opinion | 1 | 2003 | 42 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 319 | 0.050 |
Why?
|
| India | 1 | 2023 | 123 | 0.050 |
Why?
|
| Drainage | 1 | 2004 | 162 | 0.050 |
Why?
|
| Colonic Diseases | 1 | 2003 | 61 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 79 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2002 | 26 | 0.050 |
Why?
|
| Carbon Footprint | 1 | 2022 | 3 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 210 | 0.050 |
Why?
|
| Anemia, Hemolytic | 1 | 2002 | 19 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 29 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 283 | 0.050 |
Why?
|
| Gastrointestinal Agents | 1 | 2004 | 171 | 0.050 |
Why?
|
| Strategic Planning | 1 | 2021 | 2 | 0.050 |
Why?
|
| Kidney Neoplasms | 2 | 2006 | 635 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2014 | 2291 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2024 | 353 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2023 | 152 | 0.050 |
Why?
|
| Data Collection | 1 | 2003 | 375 | 0.050 |
Why?
|
| Hemothorax | 1 | 2021 | 15 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 786 | 0.050 |
Why?
|
| Preimplantation Diagnosis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Workload | 1 | 2022 | 129 | 0.050 |
Why?
|
| Gestational Age | 1 | 2022 | 323 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 76 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 70 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 385 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 360 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 69 | 0.050 |
Why?
|
| Transaminases | 2 | 2014 | 33 | 0.050 |
Why?
|
| Palliative Care | 1 | 2022 | 263 | 0.040 |
Why?
|
| Uterine Diseases | 1 | 2020 | 19 | 0.040 |
Why?
|
| Narration | 1 | 2020 | 17 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2020 | 49 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 595 | 0.040 |
Why?
|
| Uremia | 2 | 2003 | 14 | 0.040 |
Why?
|
| Chicago | 1 | 2004 | 1423 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 108 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 118 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 159 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 331 | 0.040 |
Why?
|
| Malnutrition | 1 | 2019 | 32 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1855 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2021 | 321 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2017 | 90 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1363 | 0.040 |
Why?
|
| Cholesterol | 2 | 2013 | 357 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1096 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 491 | 0.040 |
Why?
|
| Renal Veins | 2 | 2006 | 28 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2008 | 948 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 360 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 233 | 0.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 173 | 0.030 |
Why?
|
| Galactose | 2 | 2006 | 32 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2017 | 231 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 2335 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2006 | 287 | 0.030 |
Why?
|
| Necrosis | 2 | 2006 | 209 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 271 | 0.030 |
Why?
|
| Muromonab-CD3 | 2 | 2005 | 69 | 0.030 |
Why?
|
| Lupus Nephritis | 2 | 2005 | 77 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 988 | 0.030 |
Why?
|
| Spouses | 1 | 2014 | 32 | 0.030 |
Why?
|
| Bilirubin | 2 | 2005 | 129 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2004 | 301 | 0.030 |
Why?
|
| Aluminum | 1 | 1993 | 22 | 0.030 |
Why?
|
| Cold Ischemia | 1 | 2013 | 18 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2013 | 331 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 1993 | 64 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2013 | 74 | 0.030 |
Why?
|
| Perception | 1 | 2013 | 178 | 0.030 |
Why?
|
| Calcitriol | 1 | 1993 | 173 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 232 | 0.030 |
Why?
|
| Epithelium | 1 | 2013 | 325 | 0.030 |
Why?
|
| Models, Animal | 1 | 2013 | 276 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 185 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2011 | 72 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 2009 | 35 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 3443 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2009 | 74 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2009 | 126 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2009 | 99 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 738 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2008 | 43 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2009 | 296 | 0.020 |
Why?
|
| Hernia | 1 | 2008 | 23 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2004 | 559 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 261 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 242 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2007 | 8 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 251 | 0.020 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2007 | 4 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 850 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1710 | 0.020 |
Why?
|
| Common Bile Duct | 1 | 2007 | 19 | 0.020 |
Why?
|
| Surgical Mesh | 1 | 2008 | 122 | 0.020 |
Why?
|
| Family | 1 | 2009 | 325 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2007 | 38 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 35 | 0.020 |
Why?
|
| Tissue Transplantation | 1 | 2006 | 12 | 0.020 |
Why?
|
| Crohn Disease | 1 | 1993 | 758 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2006 | 96 | 0.020 |
Why?
|
| Pressure | 1 | 2007 | 165 | 0.020 |
Why?
|
| Twins, Monozygotic | 1 | 2006 | 57 | 0.020 |
Why?
|
| Half-Life | 1 | 2006 | 97 | 0.020 |
Why?
|
| Indocyanine Green | 1 | 2006 | 22 | 0.020 |
Why?
|
| Renal Artery | 1 | 2006 | 52 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 2006 | 65 | 0.020 |
Why?
|
| Hydronephrosis | 1 | 2006 | 32 | 0.020 |
Why?
|
| Lidocaine | 1 | 2006 | 65 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2006 | 36 | 0.020 |
Why?
|
| Wilms Tumor | 1 | 2006 | 38 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 2006 | 38 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3211 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1993 | 1194 | 0.020 |
Why?
|
| Factor VIIa | 1 | 2005 | 5 | 0.020 |
Why?
|
| Catheterization | 1 | 2007 | 237 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 149 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2612 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2005 | 91 | 0.020 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2006 | 71 | 0.020 |
Why?
|
| Azathioprine | 1 | 2005 | 124 | 0.020 |
Why?
|
| Hernia, Abdominal | 1 | 2004 | 14 | 0.020 |
Why?
|
| Thoracic Diseases | 1 | 2004 | 27 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 72 | 0.020 |
Why?
|
| Cholinesterases | 1 | 2004 | 17 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2005 | 53 | 0.020 |
Why?
|
| Hematoma | 1 | 2005 | 108 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 142 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2005 | 158 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2004 | 35 | 0.010 |
Why?
|
| Duodenum | 1 | 2004 | 103 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 894 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 2004 | 82 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 565 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1012 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 783 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 229 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 185 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2003 | 87 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 841 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 68 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 493 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 244 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2002 | 77 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2004 | 246 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 691 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2002 | 94 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 771 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 1528 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 809 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1940 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1715 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 866 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 948 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2004 | 548 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2002 | 170 | 0.010 |
Why?
|
| Colon | 1 | 2003 | 509 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 352 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 273 | 0.010 |
Why?
|
| Echocardiography | 1 | 2005 | 937 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2003 | 836 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 11742 | 0.010 |
Why?
|
| Hypertension | 1 | 2004 | 741 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1521 | 0.010 |
Why?
|
| Obesity | 1 | 2004 | 966 | 0.010 |
Why?
|
| Heart Failure | 1 | 2006 | 1180 | 0.010 |
Why?
|
| Intestine, Large | 1 | 1993 | 15 | 0.010 |
Why?
|
| Aluminum Hydroxide | 1 | 1993 | 3 | 0.010 |
Why?
|
| Deferoxamine | 1 | 1993 | 18 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 2347 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1993 | 124 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1993 | 293 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1993 | 245 | 0.010 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1993 | 68 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1993 | 2001 | 0.000 |
Why?
|